US 11,723,969 B2
Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
David B. Weiner, Merion, PA (US); and Devon Shedlock, Philadelphia, PA (US)
Assigned to The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed by The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed on Aug. 27, 2020, as Appl. No. 17/4,818.
Application 15/431,203 is a division of application No. 14/391,952, granted, now 9,597,388, previously published as PCT/US2013/036413, filed on Apr. 12, 2013.
Application 17/004,818 is a continuation of application No. 16/050,142, filed on Jul. 31, 2018, granted, now 10,765,733.
Application 16/050,142 is a continuation of application No. 15/431,203, filed on Feb. 13, 2017, granted, now 10,034,930.
Claims priority of provisional application 61/623,428, filed on Apr. 12, 2012.
Prior Publication US 2020/0390880 A1, Dec. 17, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); C12N 7/00 (2006.01); A61K 38/20 (2006.01); A61N 1/32 (2006.01); C07K 14/005 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 38/20 (2013.01); A61K 38/208 (2013.01); A61K 38/2086 (2013.01); A61N 1/327 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/545 (2013.01); A61K 2039/57 (2013.01); A61K 2039/572 (2013.01); A61K 2039/70 (2013.01); C07K 2319/02 (2013.01); C12N 2760/14122 (2013.01); C12N 2760/14134 (2013.01); C12N 2760/14171 (2013.01); C12N 2760/14222 (2013.01); C12N 2760/14234 (2013.01); C12N 2760/14271 (2013.01)] 11 Claims
 
1. A composition comprising one or more nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
a) a nucleic acid sequence that encodes a first consensus Marburg marburgvirus envelope glycoprotein immunogen, wherein the amino acid sequence of the first consensus Marburg marburgvirus envelope glycoprotein immunogen is selected from the group consisting of: SEQ ID NO:4 (MARV CON1), a fragment of SEQ ID NO:4 that comprises a sequence having 100% identity over 600 or more consecutive amino acids of SEQ ID NO:4, SEQ ID NO:4 (MARV CON1) linked to an IgE signal peptide, and a fragment of SEQ ID NO:4 that comprises a sequence having 100% identity over 600 or more consecutive amino acids of SEQ ID NO:4 linked to an IgE signal peptide;
b) a nucleic acid sequence that encodes a second consensus Marburg marburgvirus envelope glycoprotein immunogen, wherein the amino acid sequence of the second consensus Marburg marburgvirus envelope glycoprotein immunogen is selected from the group consisting of: SEQ ID NO:5 (MARV CON2), a fragment of SEQ ID NO:5 that comprises a sequence having 100% identity over 600 or more consecutive amino acids of SEQ ID NO:5, an amino acid sequence that is at least 95% identical to the full length of SEQ ID NO:5, a fragment of an amino acid sequence that is at least 95% identical to SEQ ID NO:5 over 600 or more consecutive amino acids, SEQ ID NO:5 (MARV CON2) linked to an IgE signal peptide, a fragment of SEQ ID NO:5 that comprises a sequence having 100% identity over 600 or more consecutive amino acids linked to an IgE signal peptide, an amino acid sequence that is at least 95% identical to the full length of SEQ ID NO:5 linked to an IgE signal peptide, and a fragment of an amino acid sequence that is at least 95% identical to SEQ ID NO:5 that comprises 600 or more consecutive amino acids of SEQ ID NO:5 linked to an IgE signal peptide; and
c) a nucleic acid sequence that encodes a second consensus Marburg marburgvirus envelope glycoprotein immunogen, wherein the amino acid sequence of the second consensus Marburg marburgvirus envelope glycoprotein immunogen is selected from the group consisting of: SEQ ID NO:6 (MARV CON3), a fragment of SEQ ID NO:6 that comprises a sequence having 100% identity over 600 or more consecutive amino acids of SEQ ID NO:6, an amino acid sequence that is at least 95% identical to the full length of SEQ ID NO:6, a fragment of an amino acid sequence that is at least 95% identical to SEQ ID NO:6 over 600 or more consecutive amino acids, SEQ ID NO:6 (MARV CON3) linked to an IgE signal peptide, a fragment of SEQ ID NO:6 that comprises a sequence having 100% identity over 600 or more consecutive amino acids linked to an IgE signal peptide, an amino acid sequence that is at least 95% identical to the full length of SEQ ID NO:6 linked to an IgE signal peptide, and a fragment of an amino acid sequence that is at least 95% identical to SEQ ID NO:6 that comprises 600 or more consecutive amino acids of SEQ ID NO:6 linked to an IgE signal peptide.